Sbitti Yassir, Slimani Khaoula, Debbagh Adil, Mokhlis Anouar, Kadiri Habiba, Laraqui Abdelilah, Errihani Hassan, Ichou Mohamed
Department of Medical Oncology, University Military Hospital, Rabat 10000, Morocco.
Department of Pathology, National Institute of Oncology, Rabat 10000, Morocco.
World J Oncol. 2017 Aug;8(4):105-109. doi: 10.14740/wjon1043w. Epub 2017 Aug 27.
Patients with visceral crisis from luminal metastatic breast cancer (mBC) are often treated with palliative chemotherapy. No studies have analyzed the aggressiveness of the care in visceral crisis from luminal mBC patients. The objective of this study was to assess practices in this setting in a university medical oncology department.
This retrospective study included all patients who were managed for luminal mBC between January 2013 and April 2016. The analysis focused on the characteristics of the patients, the modalities of cancer treatment and delays between visceral crisis and death.
Thirty-five patients pre-treated with two hormonal therapy lines were enrolled retrospectively. Worse performance status and a higher proportion of severe organ dysfunction for luminal mBC were observed among patients with visceral crisis. Sixty-five percent of patients received cytotoxic treatment. One cycle of chemotherapy was administrated in the majority of patients. Palliative care was performed in 35% of patients. Chemotherapy did not have any significant effect on patient outcome in the present study. The mean time between visceral crisis and death was 4.7 weeks (standard deviation = 1.9).
Our study showed that visceral crisis in patients with luminal mBC is a complex problem. We need more comprehension of molecular pathogenesis to visceral crisis disease to propose efficacious treatments for these patients and to identify subgroup of patients who need chemotherapy followed by maintenance endocrine therapy.
管腔型转移性乳腺癌（mBC）发生内脏危象的患者常接受姑息化疗。尚无研究分析管腔型mBC患者内脏危象时的积极治疗情况。本研究的目的是评估一所大学医学肿瘤内科在这种情况下的治疗实践。
这项回顾性研究纳入了2013年1月至2016年4月期间接受管腔型mBC治疗的所有患者。分析重点在于患者特征、癌症治疗方式以及内脏危象与死亡之间的间隔时间。
回顾性纳入了35例接受过两线内分泌治疗的患者。在内脏危象患者中观察到管腔型mBC患者的体能状态较差，严重器官功能障碍的比例更高。65%的患者接受了细胞毒性治疗。大多数患者接受了一个周期的化疗。35%的患者接受了姑息治疗。在本研究中，化疗对患者预后没有任何显著影响。内脏危象与死亡之间的平均时间为4.7周（标准差 = 1.9）。
我们的研究表明，管腔型mBC患者的内脏危象是一个复杂的问题。我们需要更深入了解内脏危象疾病的分子发病机制，为这些患者提出有效的治疗方法，并确定需要化疗后进行维持内分泌治疗的患者亚组。
